Genitourinary Cancers | Matthew R Smith, MD, PhD

59:09
 
Share
 

Manage episode 235314497 series 1464352
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer — Part 2: Our one-on-one interview with Dr Smith featuring emerging research and cases from his practice.

  • Recent advances in the treatment of nonmetastatic CRPC (00:00)
  • Effect of PSA doubling time on prognosis for patients with nonmetastatic disease (3:01)
  • PSA doubling time and clinical decision-making for patients with M0 disease (7:59)
  • Counseling patients with nonmetastatic disease about goals of therapy and expected side effects (10:26)
  • Similarities and differences in the design, entry criteria and efficacy endpoints among the ARAMIS, SPARTAN and PROSPER trials (13:25)
  • Comparison of the side-effect profiles of apalutamide, enzalutamide and darolutamide (15:35)
  • Counseling patients receiving long-term ADT about treatment-related fatigue (18:35)
  • Comparison of primary (metastasis-free survival) and secondary outcomes among the ARAMIS, SPARTAN and PROSPER trials (20:32)
  • Choosing among darolutamide, apalutamide and enzalutamide (22:45)
  • SPARTAN trial: PFS2 improvement with apalutamide for high-risk nonmetastatic CRPC (24:42)
  • Outcomes, tolerability and appropriate use of abiraterone in combination with prednisone (26:27)
  • Similarities and differences in the design, entry criteria and efficacy endpoints between the LATITUDE (ADT with abiraterone/prednisone or placebo) and ARCHES (ADT with enzalutamide or placebo) trials for patients with metastatic HSPC (29:46)
  • Key clinical and practical factors guiding the selection of docetaxel versus abiraterone/prednisone for metastatic HSPC (35:39)
  • Perspective on the intensification of therapy for patients with metastatic HSPC and suboptimal responses to ADT (39:08)
  • Spectrum and frequency of somatic and germline DNA repair gene mutations in prostate cancer; activity of PARP inhibitors in patients with metastatic CRPC (40:57)
  • Incidence of MSI-H/dMMR molecular phenotype in patients with prostate cancer; indications for testing and current role of immune checkpoint inhibitors (46:37)
  • Results of a Phase II prospective trial of lutetium-177-PSMA-617 theranostics in metastatic CRPC (50:42)
  • Novel immune checkpoint inhibitor-based combinations for metastatic CRPC (56:08)

Select publications

2168 episodes available. A new episode about every 0 hours averaging 70 mins duration .